However, our previous studies indicated that the high expression of Excision Repair Cross-Complementation Group 1 (ERCC1) contributes to lower efficiency of chemotherapy, poor response to radiotherapy, and poor prognosis in colorectal cancer [8,9,10]. Here, ERCC1 is linked to colorectal cancer.